Business Context and Reporting Period
This Form 8-K is a current report filed by Aziyo Biologics, Inc. (not Elutia Inc.) on August 11, 2022. The filing serves to announce the company's financial results for the quarter ended June 30, 2022. The full details of these results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K filing.
Material Changes
The filing does not explicitly list material changes versus the prior comparable period within the text provided. It only indicates that the results for the quarter ended June 30, 2022, have been announced.
Guidance, Outlook, and Risks
The text does not provide specific guidance, outlook, management commentary, risks, or contingencies. It notes that the information in this report (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is Aziyo Biologics, Inc. (Ticker: AZYO), not Elutia Inc.
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended June 30, 2022.
- Confirm the company's status as an emerging growth company as indicated by the checkmark in the filing.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.